\
&
Contact us
\
&
Contact us
Published on | 6 months ago
Programmes Agro-Food, EnvironmentThe European Union has historically excelled in life sciences. However in the last decades they are losing ground on their international competitors. The upcoming European Life Sciences Strategy want to reverse this evolution and the European Commission would like to receive feedback from interested parties on this new strategy. You can give your view on this website. The deadline for feedback is the 17th of April.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
AI Continent Advanced Digital Skills Deployment: Best use of technologies European Digital Innovation Hubs
The next round of Digital Europe calls has been published on the Funding & Tenders Portal of the European Commission. This next round comprises 14 call topics in total, covering the subdomains AI, data & cloud (see call topics here and here) Advanced Digital Skills Deployment European Digital Innovation Hubs The calls will o... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
